文献速递白血病淋巴瘤

转录重塑决定急性淋巴细胞白血病对坏死性凋亡的治疗易感性

Transcriptional remodeling shapes therapeutic vulnerability to necroptosis in acute lymphoblastic leukemia.
PubMed 文献 · Blood · 2025-01-01

该研究探讨急性淋巴细胞白血病(ALL)中坏死性凋亡的调控机制,通过骨髓微环境模型的离体药物反应谱发现坏死性凋亡诱导与组蛋白去乙酰化酶(HDAC)抑制具有强协同作用,转录组分析和体内CRISPR筛选鉴定出SP1、p300和HDAC2驱动的基因调控环路,联合诱导坏死性凋亡与HDAC抑制在患者来源人白血病模型中显示强体内抗白血病活性。

要点

  • ALL具有RIPK1依赖性坏死性凋亡倾向,可由SMAC模拟物激活。
  • HDAC抑制与坏死性凋亡诱导在骨髓微环境模型中显示强协同作用。
  • SP1、p300和HDAC2构成驱动坏死性凋亡的基因调控环路。

核心结论

  • 坏死性凋亡激活的转录依赖性是一种关键调控机制,鉴定出新的干预靶点,提出利用非凋亡性细胞死亡通路根除耐药疾病的策略。

研究设计与样本

  • 研究采用离体药物反应谱分析、转录组分析和功能体内CRISPR筛选,并在患者来源人白血病模型中进行验证。

主要发现

  • 在骨髓微环境模型的离体药物反应谱中,坏死性凋亡诱导与HDAC抑制显示强协同作用。
  • 转录组分析和功能体内CRISPR筛选鉴定出通过主转录调控因子SP1、p300和HDAC2驱动坏死性凋亡的基因调控环路。
  • 缺失SP1或p300赋予对坏死性凋亡的抗性,而HDAC2缺失使细胞对SMAC模拟物诱导的RIPK1依赖性细胞死亡敏感。
  • 联合坏死性凋亡诱导与HDAC抑制在患者来源人白血病模型中显示强体内抗白血病活性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Insufficient eradication of cancer cells and survival of drug tolerant clones are major relapse driving forces. Underlying molecular mechanisms comprise activated prosurvival and antiapoptotic signaling, leading to insufficient apoptosis and drug resistance. The identification of programmed cell death pathways alternative to apoptosis opens up possibilities to antagonize apoptosis escape routes. We have earlier shown that acute lymphoblastic leukemia (ALL) harbors a distinct propensity to undergo cell death by receptor-interacting protein kinase 1 (RIPK1)-dependent necroptosis, activated by small-molecule second mitochondria-derived activators of caspase (SMAC) mimetics. Despite demonstrated safety and tolerability of SMAC mimetics in clinical trials, their efficacy as single agent seems still limited, highlighting the need for combinatorial treatments. Here, we investigate so far unexplored regulatory mechanisms of necroptosis and identify targets for interference to augment the necroptotic antileukemia response. Ex vivo drug response profiling in a model of the bone marrow microenvironment reveals powerful synergy of necroptosis induction with histone deacetylase (HDAC) inhibition. Subsequent transcriptome analysis and functional in vivo CRISPR screening identify gene regulatory circuitries through the master transcription regulators specificity protein 1 (SP1), p300, and HDAC2 to drive necroptosis. Although deletion of SP1 or p300 confers resistance to necroptosis, loss of HDAC2 sensitizes cells to RIPK1-dependent cell death by SMAC mimetics. Consequently, our data inform strong in vivo antileukemic activity of combinatorial necroptosis induction and HDAC inhibition in patient-derived human leukemia models. Thus, transcriptional dependency of necroptosis activation is a key regulatory mechanism that identifies novel targets for interference, pointing out a strategy to exploit alternative nonapoptotic cell death pathways to eradicate resistant disease.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Saorin A, Dehler A, Galvan B, et al. Transcriptional remodeling shapes therapeutic vulnerability to necroptosis in acute lymphoblastic leukemia. Blood. 2025. PMID: 40359431. doi:10.1182/blood.2025028938

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。